Tommy Wu, BA

Articles by Tommy Wu, BA

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer

ByStanley E. Waintraub, MD,Donna McNamara, MD,Deena Mary Atieh Graham, MD,Andrew L. Pecora, MD,John Min, BS,Tommy Wu, BA,Hyun Gi Noh, MSC,Jacqueline Connors, RN, OCN,Ruth Pe Benito, MPH, BS,Kelly Choi, MD,Eric Schultz, BS,Stuart L. Goldberg, MD

December 20th 2017

Universal gene expression profiling of patients with stage II breast cancer resulted in outpatient savings of $11,000 (inclusive of testing costs) within 6 months of initiation of medical therapy.

Latest Updated Articles

Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer
Published: December 20th 2017 | Updated:

Trending on CGTlive®

Sarepta Therapeutics’ Limb-Girdle Muscular Dystrophy Gene Therapy SRP-9003 Produces “Robust Expression” of β-SG in Phase 3 Trial

AAVantgarde’s Stargardt Gene Therapy AAVB-039 Garners FDA Orphan Drug Designation, Cleared for Trial in UK

Home

About Us

News